| Record ID | ia:questioningchemo00moss |
| Source | Internet Archive |
| Download MARC XML | https://archive.org/download/questioningchemo00moss/questioningchemo00moss_marc.xml |
| Download MARC binary | https://www.archive.org/download/questioningchemo00moss/questioningchemo00moss_meta.mrc |
LEADER: 01836cam 2200505 a 4500
001 ocm32167334
003 OCoLC
005 20101201185241.0
008 950228s1995 nyu 001 0 eng
010 $a 95011440
040 $aDLC$cDLC$dNLM$dBAKER$dBTCTA$dYDXCP
016 7 $a9514355$2DNLM
020 $a188102525X
020 $a9781881025252
035 $a(OCoLC)32167334
050 00 $aRC271.C5$bM67 1995
060 00 $a1995 I-597
060 10 $aQV 267$bM913q 1995
082 00 $a616.994/061$220
100 1 $aMoss, Ralph W.
245 10 $aQuestioning chemotherapy/$cby Ralph W. Moss.
260 $aBrooklyn, NY :$bEquinox Press,$cc1995.
300 $a210 p. ;$c22 cm.
504 $aIncludes bibliographical references (p. 192-209) and index.
650 0 $aAntineoplastic agents$xSide effects.
650 0 $aAntineoplastic agents$xToxicology.
650 0 $aCancer$xChemotherapy$xComplications.
650 0 $aAntineoplastic agents$xEffectiveness.
650 12 $aAntineoplastic Agents$xadverse effects.
650 22 $aNeoplasms$xdrug therapy.
650 22 $aAntineoplastic Agents$xtherapeutic use.
650 22 $aChemotherapy, Adjuvant$xadverse effects.
650 22 $aDrug Therapy$xutilization.
938 $aBaker & Taylor$bBKTY$c19.95$d14.96$i188102525X$n0002648359$sactive
938 $aBaker and Taylor$bBTCP$n95011440
938 $aYBP Library Services$bYANK$n1670508
952 $a32167334$zDLC$bLIBRARY OF CONGRESS$hFull$iLCC$jNLM$kDDC$u20100128
952 $a274808250$zSTF$bSTANFORD UNIV LIBR$hFull$iLCC$kDDC$u20100709
952 $a487162862$zN15$bNEW YORK UNIV, GROUP BATCHLOAD$hFull$iLCC$kDDC$u20100716
029 1 $aNLM$b9514355
029 1 $aNZ1$b4628034
029 1 $aAU@$b000011534608
029 1 $aUNITY$b034213902
994 $aZ0$bPMR
948 $hNO HOLDINGS IN PMR - 141 OTHER HOLDINGS